Department of Defense & Industry Daily News
Advertisement
Defense program acquisition news, budget data, market briefings
  • Contact
    Editorial
    Advertising
    Feedback & Support
    Subscriptions & Reports
  • Subscribe
    Paid Subscription
    in-depth program analysis & data sets
    Free Email Newsletter
    quick daily updates
    Google+ Twitter RSS
  • Log in
    Forgot your password?
    Not yet a subscriber? Find out what you have been missing.
Archives by date > 2011 > October

$109.6M for Improved B-2A Bomber Heat Shields

Oct 02, 2011 13:16 UTC

B-2A

B-2A Spirit

In September 2011, Northrop Grumman Aerospace Systems in Palmdale, CA received a $109.6 million a firm-fixed-price contract “for aft decks applicable to B-2 aircrafts.” We asked Northrop Grumman about this, and they said that this stealth bomber contract was about buying spares with improved durability. The aft deck shields the composite airframe from the heat of the engines’ exhaust, and the redesign follows a thorough thermal and structural analysis of the aft deck, its adjoining structures and the operating environment.

Work will be performed in Palmdale, CA and in St. Augustine, FL, until April 19/16. The Defense Logistics Agency Aviation at Tinker Air Force Base, OK manages the contract (SPRTA1-11-C-0112). While the B-2 fleet’s FAST umbrella contract covers most modifications and maintenance, this is separate from FAST.

DARPA Looking to Harness RNA for Vaccines

Oct 02, 2011 12:40 UTC

Advertisement
RNA/DNA

RNA vs. DNA

In September 2011, the RN Armor Vax international consortium in Orlando, FL received a $17.3 million technology investment agreement from US DARPA. Their research and development program is designed to “identify, investigate, and develop candidate RNA vaccines against infectious disease.” Work will be performed in Orlando, FL (19.59%); Lyon, France (11.93%); Tubingen, Germany (56.62%); and Nantes, France (11.86%). The work is expected to be completed by September 2015. The US Defense Advanced Research Projects Agency manages the contract (HR0011-11-3-0001).

RNA is very useful for synthesizing proteins. This has led to research into ways of using it as a trigger, so that cells synthesize very specific proteins that will kill tumor cells, trigger correct immune responses, or perform other related functions. Dendritic immune cells, for instance, which stimulate the production of defensive killer T-cells, are a useful vector for RNA codes that direct the production of specific proteins. Another interesting function is RNA-enhanced vaccines using “silencing RNA,” which shuts down specific proteins in the cells that process a vaccine. That lets the vaccine offer more of an antibody response, which is very useful for parasitic infections, or create more of a cellular-kill response for viral infections.

« Previous 1 … 4 5 6
Advertisement
White Papers & Events
Advertisement
October 2011
SMTWTFS
« Sep Nov »
 1
2345678
9101112131415
16171819202122
23242526272829
3031 
Advertisement

© 2004-2022 Defense Industry Daily, LLC | About Us | Images on this site | Privacy Policy

Contact us: Editorial | Advertising | Feedback & Support | Subscriptions & Reports

Follow us: Twitter | Google+

Stay Up-to-Date on Defense Programs Developments with Free Newsletter

DID's daily email newsletter keeps you abreast of contract developments, pictures, and data, put in the context of their underlying political, business, and technical drivers.